GLP-1R
GLP-1 receptor signalling
GLP-1 is a gut hormone released after eating. Drugs that activate the GLP-1 receptor act on the pancreas (to release insulin in a glucose-dependent way), the brain (to reduce appetite and food reward) and the stomach (to slow emptying). The effect on body weight comes mainly from reduced appetite over time.
Plain-English explanation
GLP-1 is a gut hormone released after eating. Drugs that activate the GLP-1 receptor act on the pancreas (to release insulin in a glucose-dependent way), the brain (to reduce appetite and food reward) and the stomach (to slow emptying). The effect on body weight comes mainly from reduced appetite over time.
Research-level explanation
GLP-1 receptor agonism is the most clinically validated mechanism in modern obesity and type 2 diabetes pharmacology. Semaglutide, liraglutide and dulaglutide are licensed UK medicines acting principally through GLP-1 receptor agonism; tirzepatide and the triple agonists also include GLP-1 receptor activity. The SELECT cardiovascular outcomes trial of semaglutide and the FLOW kidney outcomes trial of semaglutide demonstrated outcome benefits in defined populations.
Common misconceptions
| Common claim | More accurate framing |
|---|---|
| GLP-1 RAs cause weight loss only by slowing stomach emptying. | Central appetite and food-reward effects in the brain appear to be the principal contributors to chronic weight reduction; gastric-emptying effects exhibit tachyphylaxis on chronic dosing. |
| GLP-1 RAs always lower cardiovascular risk. | Cardiovascular benefit has been shown in specific populations (e.g., SELECT for semaglutide in adults with overweight/obesity and pre-existing CVD without diabetes; LEADER for liraglutide in T2D with high CV risk). It is not automatic for every agent, dose or population. |
Safety relevance
Relevant to gastrointestinal adverse events, gallbladder disease in the context of rapid weight reduction, pancreatitis signal monitoring, and (for diabetes use) hypoglycaemia risk when combined with insulin or sulfonylureas.
- GLP-1 receptor agonism does not automatically translate into the same magnitude of weight or cardiovascular effect across different agents.
- Pre-clinical receptor selectivity does not predict trial-measured outcomes.
Related peptide profiles
Related trials
Related conditions
Related safety signals
Sources are tagged by class. Regulatory documents, peer-reviewed publications and trial registry records are preferred. Manufacturer disclosures and conference material are accepted where peer-reviewed publication is not yet available; preprints are flagged.
- Peer-reviewed publicationWilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021.
- Peer-reviewed publicationLincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med 2023.
- Peer-reviewed publicationPerkovic V et al. Effects of semaglutide on chronic kidney disease in type 2 diabetes (FLOW). N Engl J Med 2024.
- Peer-reviewed publicationMarso SP et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). N Engl J Med 2016.
- Regulatory document (MHRA/EMA/FDA)MHRA — Medicines and Healthcare products Regulatory Agency
UK regulatory authority for medicines and medical devices
- Regulatory document (MHRA/EMA/FDA)European Medicines Agency — Scientific guidelines
EMA scientific guidelines covering pharmacodynamic mechanisms
- Editorial synthesisSite editorial synthesis — Metabolic Peptides
Editorial summary of mechanism profiles on this site